Clinical trials: Cryptococcal Meningitis
Cryptococcal Meningitis, HIV Infections
AmB Dose for Cryptococcal Meningitis
Cryptococcal meningitis (CM) is one of the leading opportunistic infections and one of the most common causes of death in AIDS patients. Amphotericin B (AmB) is the corner stone in CM treatment.
- Trial name
- NCT04140461
- Testing
- Amphotericin B, Flucytosine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Public Health Clinical Center
Meningitis, Cryptococcal, HIV Infections
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients.
- Trial name
- NCT00002077
- Testing
- Fluconazole
- Where
- 4 sites in United States
- Sponsor
- Pfizer
Cryptococcal Meningitis, HIV
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa
The aim of the trial is to demonstrate that in a sub-Saharan African setting, the association of: 1. Oral treatment : high dose of fluconazole (1600mg/d) associated with flucytosine (100 mg/kg/j) as induction therapy 2.
- Trial name
- Flucocrypto (NCT01715922)
- Testing
- Fluconazole, Flucytosine, lumbar punctures
- Where
- 7 sites in Burundi, Côte d’Ivoire
- Volunteers
- 41 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Cryptococcal Meningitis
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
This study is designed as two sequential trials. The first is a phase I open label trial to evaluate the safety and tolerability of MAT2203.
- Trial name
- EnACT (NCT04031833)
- Testing
- MAT2203, Amphotericin B
- Where
- Uganda
- Volunteers
- 178 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Cryptococcal Infection, Cryptococcal Pneumonia
Fungal Infection Susceptibility
The protocol will be carried out in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) and the following United States Code of…
- Conditions
- Cryptococcal Infection, Cryptococcal Pneumonia, Pulmonary Cryptococcosis, Cryptococcal Meningitis
- Trial name
- NCT00001352
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis, Cryptococcal, HIV Infections
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS
To compare the safety and effectiveness of fluconazole with that of placebo as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002294
- Testing
- Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Cryptococcal Meningitis
CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa
The study will determine if the initiation of a 'screen and treat' program for cryptococcal disease among HIV positive individuals decreases morbidity and mortality among individuals with CD4 count < 100 cells/mm3.
- Trial name
- CryptoART (NCT02434172)
- Testing
- Pre-emptive screening and treatment for cryptococcal disease
- Where
- Zimbabwe
- Volunteers
- 1,333 people
- Sponsor
- University of Zimbabwe
Meningitis, Cryptococcal, HIV Infections
The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis
To evaluate the safety of escalating doses of RMP-7 administered in persons with HIV infection and cryptococcal meningitis and to determine the MTD of the drug.
- Trial name
- NCT00002316
- Testing
- Lobradimil, Amphotericin B
- Where
- 11 sites in United States
- Sponsor
- Alkermes, Inc.
AIDS-Related Opportunistic Infections, Meningo-encephalitis
Driving Reduced AIDS-associated Meningo-encephalitis Mortality
The DREAMM project is investigating whether the DREAMM interventions (1) Health system strengthening, 2) Co-designed education programs tailored to frontline healthcare workers, 3) Implementation of a diagnostic and treatment…
- Conditions
- AIDS-Related Opportunistic Infections, Meningo-encephalitis, Cryptococcal Meningitis, Bacterial Meningitis
- Trial name
- DREAMM (NCT03226379)
- Testing
- DREAMM
- Where
- 5 sites in Cameroon, Malawi and 1 more
- Volunteers
- 495 people
- Sponsor
- St George's, University of London
Cryptococcal Meningitis, HIV Infections
Cryptococcal Optimal ART Timing Trial
The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital discharge results in superior survival compared to…
- Conditions
- Cryptococcal Meningitis, HIV Infections, AIDS
- Trial name
- COAT (NCT01075152)
- Testing
- efavirenz, nucleoside
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 177 people
- Sponsor
- University of Minnesota
Cryptococcal Meningitis
Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
Cryptococcal meningitis (CM) is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy.
- Trial name
- NCT06414512
- Testing
- AMBITION trial control, Flucytosine
- Where
- 2 sites in Uganda
- Volunteers
- 48 people
- Sponsor
- University of Minnesota
Meningitis, Cryptococcal, HIV Infections
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the…
- Trial name
- NCT00000639
- Testing
- Itraconazole, Flucytosine, Fluconazole
- Where
- 24 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis, Cryptococcal, HIV Infections
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS
To compare the safety and effectiveness of a new drug, fluconazole, with that of the usual therapy, amphotericin B, in the prevention of a relapse of cryptococcal meningitis (CM) in patients with AIDS who have been successfully…
- Trial name
- NCT00001017
- Testing
- Fluconazole, Amphotericin B
- Where
- 28 sites in United States
- Volunteers
- 330 people
- Sponsor
- Pfizer
Cryptococcal Meningitis
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
This study will examine the effectiveness and safety of a combination treatment for cryptococcal meningitis, a fungal infection common in persons with acquired immune deficiency syndrome (AIDS) in the developing world.
- Trial name
- NCT00145249
- Testing
- Amphotericin B, Fluconazole
- Where
- 15 sites in United States, Thailand
- Volunteers
- 143 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, Cryptococcal Meningitis
Vietnam Cryptococcal Retention in Care Study - Version 2.1
This is a multicenter prospective cohort evaluation of the implementation of a cryptococcal antigen (CrAg) screening program at selected outpatient HIV clinics (OPCs) and network laboratories in Vietnam.
- Conditions
- HIV/AIDS, Cryptococcal Meningitis, Opportunistic Infections, HIV Related, Cryptococcosis
- Trial name
- NCT03267407
- Testing
- Preemptive high-dose Fluconazole
- Where
- Vietnam
- Volunteers
- 1,184 people
- Sponsor
- National Hospital for Tropical Diseases, Hanoi, Vietnam
Meningitis, Cryptococcal, HIV Infections
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.
- Trial name
- NCT00002075
- Testing
- Flucytosine, Fluconazole, Amphotericin B
- Where
- United States
- Sponsor
- Pfizer
Meningitis, Cryptococcal, HIV Infections
Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome
To evaluate the safety, tolerance and efficacy of three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B) in patients with AIDS and cryptococcal meningitis.
- Trial name
- NCT00002019
- Testing
- Amphotericin B, Lipid-based, Amphotericin B
- Where
- 19 sites in United States
- Sponsor
- Liposome
Neurological Disorders, Cerebral Malaria
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
The impact of neurological disorders is enormous worldwide, and it is increased in poor settings, due to lack of diagnosis and treatment facilities as well as delayed management.
- Conditions
- Neurological Disorders, Cerebral Malaria, Bacterial Meningitis, Central Nervous System Tuberculosis
- Trial name
- Nidiag-Neuro (NCT01589289)
- Testing
- Immunochromatographic HAT tests (DSD), Card Agglutination Trypanosoma Test, TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)
- Where
- Democratic Republic of the Congo
- Volunteers
- 352 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Meningitis, Cryptococcal, HIV Infections
Dexamethasone in Cryptococcal Meningitis
To evaluate the effect of corticosteroids on reducing elevated intracranial pressure in cryptococcal meningitis. To evaluate the safety of corticosteroids in patients with cryptococcal meningitis and intracranial hypertension.
- Trial name
- NCT00000776
- Testing
- Flucytosine, Fluconazole, Amphotericin B
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cryptococcal Meningitis
Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report
CRICS financial report for the first budget year of the study
- Trial name
- NCT02955862
- Testing
- Vietnam Cryptococcal Retention in Care Study (CRICS)
- Where
- Vietnam
- Volunteers
- 1,177 people, healthy volunteers welcome
- Sponsor
- National Hospital for Tropical Diseases, Hanoi, Vietnam